Are you over 18 and want to see adult content?
More Annotations
A complete backup of stevemckelvie.wordpress.com
Are you over 18 and want to see adult content?
Professional Forex Broker | CFDs, Gold and Oil Trading - FXGROW
Are you over 18 and want to see adult content?
Noclegi w Wiciu w ponad 90 obiektach, atrakcje, gastronomia, pogoda, informacje, imprezy, zdjęcia, filmy.
Are you over 18 and want to see adult content?
Atlantic City Casino Hotel | Hard Rock Hotel & Casino
Are you over 18 and want to see adult content?
Download responsive landing page designs and website design
Are you over 18 and want to see adult content?
Cat Crib Cat Hammock: The best cat hammock for your kitty
Are you over 18 and want to see adult content?
DiabloGolf.com: Golf Handicap Tracker and Calculator App for iPhone and Android Smartphones
Are you over 18 and want to see adult content?
บรรษัทประกันสินเชื่ออุตสาหกรรมขนาดย่อม (บสย.)
Are you over 18 and want to see adult content?
News 96.5 WDBO | Where Orlando Turns First For Breaking News, Weather, and Traffic
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of prishtinainsight.com
Are you over 18 and want to see adult content?
A complete backup of awesomeolofsson.se
Are you over 18 and want to see adult content?
A complete backup of renegade-angel.ch
Are you over 18 and want to see adult content?
A complete backup of one-hour-payday-loans.net
Are you over 18 and want to see adult content?
A complete backup of tntamusements.com
Are you over 18 and want to see adult content?
A complete backup of poppyshop.org.uk
Are you over 18 and want to see adult content?
A complete backup of greenworldinvestor.com
Are you over 18 and want to see adult content?
A complete backup of delta-esourcing.com
Are you over 18 and want to see adult content?
A complete backup of thejuicemedia.com
Are you over 18 and want to see adult content?
Text
YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
MARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases.ERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global Medical DEVELOPING BREAKTHROUGH TREATMENTS FOR DRY EYE DISEASE Indication Target Pre-clinical IND-enabling Phase 1/2a Phase 2b Phase 3 AXR-159 (eyedrop) DED α4β1, α4β7 AXR-270 (cream) Acute DED,Blepharitis GR
HOW TO GET DEVICES APPROVED 510(k) Examples » “The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging (SPECTRALIS HRA+OCT and DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report.DR. RAFIQ HASAN
Rafiq trained as a physician in London and following 3 years in clinical practice entered the pharmaceutical industry. Over the subsequent 18 years he gained experience in a variety of clinical and commercial roles of increasing responsibility both in the UK and at a global level at Novartis and Bayer. Prior to joining Bayer in hiscurrent role
OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website. OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-houseYUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
MARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases.ERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global Medical DEVELOPING BREAKTHROUGH TREATMENTS FOR DRY EYE DISEASE Indication Target Pre-clinical IND-enabling Phase 1/2a Phase 2b Phase 3 AXR-159 (eyedrop) DED α4β1, α4β7 AXR-270 (cream) Acute DED,Blepharitis GR
HOW TO GET DEVICES APPROVED 510(k) Examples » “The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging (SPECTRALIS HRA+OCT and DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report.DR. RAFIQ HASAN
Rafiq trained as a physician in London and following 3 years in clinical practice entered the pharmaceutical industry. Over the subsequent 18 years he gained experience in a variety of clinical and commercial roles of increasing responsibility both in the UK and at a global level at Novartis and Bayer. Prior to joining Bayer in hiscurrent role
OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house APELLIS BUILDING ON ITS PLATFORM WITH APL-2 FOR GEOGRAPHIC Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11 INDUSTRY--INDUSTRY-CASE-STUDY- European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2RAN-YAM--NOVASIGHT-
European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2 RON-SCHNEIDER--BEYEONICS European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2 MOSHE-WEINSTEIN---EVERADS- European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2 OYSTER POINT’S JOHN SNISARENKO SAYS FOLLOW THE SCIENCE AND John Snisarenko, MBA, CCO of Oyster Point Pharma, developed his interest in eye care at age 13, upon being fitted with contact lenses by an optometrist.. That interest led him through positions with several eye-care companies and eventually to Oyster Point Pharma, which, Snisarenko says, has “a very unique approach to dry eye.” MIKI-OLSHANKSKY---ELGAN- European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2 DAPHNE-HAIM-LANGFORD,-PHD--TARSIER-PHARMA- European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2 YARIV-BAR-ON---BLINK-ENERGY- European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2 OISABOUT USNEWSPODCASTSVIDEOSEVENTSGET INVOLVED OIS. The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website. OIS DIGITAL INNOVATION SHOWCASE PRESENTING COMPANIES May 20th, 2021 at the following time: 1:00PM - 4:30PM Eastern Time OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS ISRAEL INNOVATION SHOWCASE 2021 Promedica International. Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California.YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASE If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent infringement investigation into a Novartis complaint against rival Regeneron Pharmaceuticals, Sandoz, a Novartis division, said it would initiate enrollment in a confirmatory Phase III trial for a biosimilar candidate of Eylea, Regeneron’s anti-VEGFERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases.OIS
OIS. The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website. OIS DIGITAL INNOVATION SHOWCASE PRESENTING COMPANIES May 20th, 2021 at the following time: 1:00PM - 4:30PM Eastern Time OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS ISRAEL INNOVATION SHOWCASE 2021 Promedica International. Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California.YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASE If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent infringement investigation into a Novartis complaint against rival Regeneron Pharmaceuticals, Sandoz, a Novartis division, said it would initiate enrollment in a confirmatory Phase III trial for a biosimilar candidate of Eylea, Regeneron’s anti-VEGFERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases. OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS RETINA INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website.BIOLIGHT-2021
2021 EVENTS. Israel Innovation Showcase - June 10. Retina Innovation Showcase - July 1. European Innovation Showcase - July 22. Glaucoma Innovation Showcase - October 21. Drug Delivery Innovation Showcase - November 11. 2021 OIS Year in Review - December 2. - PAST EVENTS. GETINVOLVED.
APELLIS BUILDING ON ITS PLATFORM WITH APL-2 FOR GEOGRAPHIC Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11ISRAEL-THANKYOU
European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2IATI LOGO | OIS
Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11 OYSTER POINT’S JOHN SNISARENKO SAYS FOLLOW THE SCIENCE AND John Snisarenko, MBA, CCO of Oyster Point Pharma, developed his interest in eye care at age 13, upon being fitted with contact lenses by an optometrist.. That interest led him through positions with several eye-care companies and eventually to Oyster Point Pharma, which, Snisarenko says, has “a very unique approach to dry eye.”BEYEONICS-WEB
Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11ISRAEL-LOGO-MC
European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11; 2021 OIS Year in Review - December 2OIS PODCAST
Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11 OISABOUT USNEWSPODCASTSVIDEOSEVENTSGET INVOLVED OIS. The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website. OIS DIGITAL INNOVATION SHOWCASE PRESENTING COMPANIES May 20th, 2021 at the following time: 1:00PM - 4:30PM Eastern Time OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-houseBIOLIGHT-2021
2021 EVENTS. Israel Innovation Showcase - June 10. Retina Innovation Showcase - July 1. European Innovation Showcase - July 22. Glaucoma Innovation Showcase - October 21. Drug Delivery Innovation Showcase - November 11. 2021 OIS Year in Review - December 2. - PAST EVENTS. GETINVOLVED.
OIS ISRAEL INNOVATION SHOWCASE 2021 Promedica International. Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California.YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASE If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent infringement investigation into a Novartis complaint against rival Regeneron Pharmaceuticals, Sandoz, a Novartis division, said it would initiate enrollment in a confirmatory Phase III trial for a biosimilar candidate of Eylea, Regeneron’s anti-VEGFERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. OISABOUT USNEWSPODCASTSVIDEOSEVENTSGET INVOLVED OIS. The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website. OIS DIGITAL INNOVATION SHOWCASE PRESENTING COMPANIES May 20th, 2021 at the following time: 1:00PM - 4:30PM Eastern Time OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-houseBIOLIGHT-2021
2021 EVENTS. Israel Innovation Showcase - June 10. Retina Innovation Showcase - July 1. European Innovation Showcase - July 22. Glaucoma Innovation Showcase - October 21. Drug Delivery Innovation Showcase - November 11. 2021 OIS Year in Review - December 2. - PAST EVENTS. GETINVOLVED.
OIS ISRAEL INNOVATION SHOWCASE 2021 Promedica International. Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California.YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASE If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent infringement investigation into a Novartis complaint against rival Regeneron Pharmaceuticals, Sandoz, a Novartis division, said it would initiate enrollment in a confirmatory Phase III trial for a biosimilar candidate of Eylea, Regeneron’s anti-VEGFERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. OIS DIGITAL INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website. OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS RETINA INNOVATION SHOWCASE Retisert ® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and otherOIS PODCAST
Welcome to Our OIS Podcast Channel. Ophthalmology’s leaders convene at the Ophthalmology Innovation Summits held several times a year. OIS Podcasts keeps the conversation going the entire year. In weekly podcasts, Host Ehsan Sadri interviews the most influential industry executives, investors, KOLs, and researchers about what they see asthe
OIS ISRAEL INNOVATION SHOWCASE 2021 Promedica International. Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. APELLIS BUILDING ON ITS PLATFORM WITH APL-2 FOR GEOGRAPHIC Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11IATI LOGO | OIS
Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11BEYEONICS-WEB
Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11 OYSTER POINT’S JOHN SNISARENKO SAYS FOLLOW THE SCIENCE AND John Snisarenko, MBA, CCO of Oyster Point Pharma, developed his interest in eye care at age 13, upon being fitted with contact lenses by an optometrist.. That interest led him through positions with several eye-care companies and eventually to Oyster Point Pharma, which, Snisarenko says, has “a very unique approach to dry eye.”OIS PODCAST
Israel Innovation Showcase - June 10; European Innovation Showcase - July 20; Glaucoma Innovation Showcase - October 21; Drug Delivery Innovation Showcase - November 11 OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website.OIS YEAR IN REVIEW
Year in Review - Industry Perspectives. Participants: Laurent Attias, SVP, Corporate Development Strategy, BD&L and M&A - Alcon. Andrew Chang, Head of Global Sales, Ophthalmic Devices and President - Carl Zeiss Meditec. Mark Hagler, SVP, Head of Ophthalmics, Oncology & LTC - Sun Pharma. Robert Kissling, MD, VP, Medical Affairs - Bausch + Lomb.YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
ERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases. DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report. DEVELOPING BREAKTHROUGH TREATMENTS FOR DRY EYE DISEASE Indication Target Pre-clinical IND-enabling Phase 1/2a Phase 2b Phase 3 AXR-159 (eyedrop) DED α4β1, α4β7 AXR-270 (cream) Acute DED,Blepharitis GR
HOW TO GET DEVICES APPROVED 510(k) Examples » “The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging (SPECTRALIS HRA+OCT and OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS DRY EYE INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website.OIS YEAR IN REVIEW
Year in Review - Industry Perspectives. Participants: Laurent Attias, SVP, Corporate Development Strategy, BD&L and M&A - Alcon. Andrew Chang, Head of Global Sales, Ophthalmic Devices and President - Carl Zeiss Meditec. Mark Hagler, SVP, Head of Ophthalmics, Oncology & LTC - Sun Pharma. Robert Kissling, MD, VP, Medical Affairs - Bausch + Lomb.YUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
ERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases. DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report. DEVELOPING BREAKTHROUGH TREATMENTS FOR DRY EYE DISEASE Indication Target Pre-clinical IND-enabling Phase 1/2a Phase 2b Phase 3 AXR-159 (eyedrop) DED α4β1, α4β7 AXR-270 (cream) Acute DED,Blepharitis GR
HOW TO GET DEVICES APPROVED 510(k) Examples » “The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging (SPECTRALIS HRA+OCT and OIS DIGITAL INNOVATION SHOWCASE 2021 Novartis. Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products. Company's Website.BIOLIGHT-2021
2021 EVENTS. Israel Innovation Showcase - June 10. Retina Innovation Showcase - July 1. European Innovation Showcase - July 22. Glaucoma Innovation Showcase - October 21. Drug Delivery Innovation Showcase - November 11. 2021 OIS Year in Review - December 2. - PAST EVENTS. GETINVOLVED.
OIS DRY EYE INNOVATION SHOWCASE PRESENTING COMPANIES 2021 Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil andOIS YEAR IN REVIEW
Year in Review - Industry Perspectives. Participants: Laurent Attias, SVP, Corporate Development Strategy, BD&L and M&A - Alcon. Andrew Chang, Head of Global Sales, Ophthalmic Devices and President - Carl Zeiss Meditec. Mark Hagler, SVP, Head of Ophthalmics, Oncology & LTC - Sun Pharma. Robert Kissling, MD, VP, Medical Affairs - Bausch + Lomb. HOW TO GET DEVICES APPROVED 510(k) Examples » “The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging (SPECTRALIS HRA+OCT andDAVID GUYER, MD
Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May to September 2013, including a $192 million IPO, a multi-tranched $125 million royalty financing deal with Novo A/S and a $50 million Series C private funding round.BOB BUTCHOFSKY
Robert Butchofsky is the Founder and CEO of Mati Therapeutics. Headquartered in Austin, Texas, Mati is developing a non-invasive sustained drug delivery platform to treat a variety of ocular diseases including glaucoma, allergy, inflammation, and dry eye. Mr. Butchofsky is the former President and CEO of QLT Inc., a publicly traded Vancouver-based biotech company. NOVARTIS STEPS UP DIGITAL STRATEGY FOR AMD TREATMENTS AND Novartis is doubling down on its mission to end preventable blindness, which has translated into a host of moves to strengthen its commitment to age-related macular degeneration (AMD) treatments and support. Its latest move is in the digital health space with the launch of a new feature on the MyTherapy app, a pill reminder and medication tracker shown to improve medication adherence. VIVID VISION PERIMETRY Vivid Vision is a venture backed startup •Vivid Vision is a 5-year-old virtual reality software company. •Beach-head product: Binocular vision testing and treatment RISUTEGANIB (LUMINATE ): POTENTIAL PARADIGM SHIFT IN THE 2 Allegro is a late stage private biotech company focused on the treatment of retinal diseases Allegro’s lead investigational drug, Risuteganib(Luminate®), is a broad-spectrum anti-integrin peptide expected to begin phase 3 DME OISABOUT USNEWSPODCASTSVIDEOSEVENTSGET INVOLVED OIS. The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS RETINA INNOVATION SHOWCASE Retisert ® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and otherYUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
DAVID GUYER, MD
Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, where he led the company through private, public and corporate financings totaling over $400 million.GAVIN HERBERT
Biography. Mr. Herbert is the Chairman Emeritus of Allergan, Inc., headquartered in Irvine, CA. Mr. Herbert, who helped found the company in 1950, served as its Chairman from 1977 to 1995 as its Chief Executive Officer from 1961-1991. Mr. Herbert is also Owner/Chairman of Roger’s Gardens, a large retail nursery in Newport Beach, CA andthe
ERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMALVINA EYDELMAN
Biography. Dr. Eydelman joined FDA in 1995 and for the last 17 years, has served as the Director of FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices (DOED), and subsequently Director of the FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices (DONED). Dr. Eydelman has been involved in all aspects of DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases. OISABOUT USNEWSPODCASTSVIDEOSEVENTSGET INVOLVED OIS. The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS RETINA INNOVATION SHOWCASE Retisert ® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and otherYUVAL BINUR, PHD
Biography. DR. Binur has over 30 years of worldwide venture capital and investment experience. Since 2010, Dr. Binur expend his operations to the emerging markets, mostly in China, spending there substantial part of his time. In 2000, Dr. Binur co-founded Accelerated Technologies, Inc. – a highly differentiated investment firm focusedon
DAVID GUYER, MD
Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, where he led the company through private, public and corporate financings totaling over $400 million.GAVIN HERBERT
Biography. Mr. Herbert is the Chairman Emeritus of Allergan, Inc., headquartered in Irvine, CA. Mr. Herbert, who helped found the company in 1950, served as its Chairman from 1977 to 1995 as its Chief Executive Officer from 1961-1991. Mr. Herbert is also Owner/Chairman of Roger’s Gardens, a large retail nursery in Newport Beach, CA andthe
ERIN POWERS
Erin Schallhorn Powers is the Senior Director for Medical Affairs and Professional Education for Carl Zeiss Meditec’s Ophthalmic Devices business unit. Erin has been in the ophthalmic industry for fifteen years, holding positions at VISX, AMO, and Alcon before joining Zeiss in 2016. In her current role, she established the Global MedicalMALVINA EYDELMAN
Biography. Dr. Eydelman joined FDA in 1995 and for the last 17 years, has served as the Director of FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices (DOED), and subsequently Director of the FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices (DONED). Dr. Eydelman has been involved in all aspects of DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report. DEB JORN | OPHTHALMOLOGY INNOVATION SUMMIT Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases. OIS GENE THERAPY INNOVATION SHOWCASE 2021 Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house OIS DIGITAL INNOVATION SHOWCASE PRESENTING COMPANIES May 20th, 2021 at the following time: 1:00PM - 4:30PM Eastern Time OIS DRY EYE INNOVATION SHOWCASE Israel Innovation Showcase - June 10. Retina Innovation Showcase - July 1. European Innovation Showcase - July 22. Diagnostics Innovation Showcase - September 30. Glaucoma Innovation Showcase - October 21. Drug Delivery Innovation Showcase - November 11. 2021 OIS Year in Review - December 2. -BIOLIGHT-2021
2021 EVENTS. Israel Innovation Showcase - June 10. Retina Innovation Showcase - July 1. European Innovation Showcase - July 22. Glaucoma Innovation Showcase - October 21. Drug Delivery Innovation Showcase - November 11. 2021 OIS Year in Review - December 2. - PAST EVENTS. GETINVOLVED.
MARC ABITBOL, PHD
DR. MARC ABITBOL is the Chairman and CEO of VISIONIX Ltd., a company he founded in 1994. Prior to founding VISIONIX, Dr. Abitbol gained over 15 years of experience in the electro-optic industry at the Israeli company, ELOP -Electro Optics Industries Ltd., and at the French company, Bertin Technologies. DYNAMIC MEIBOMIAN GLAND IMAGING •Meibomian gland structure is critical for severity assessment1 3 Why Image Meibomian Glands? 1. Craig JP, Nichols KK, AkpekEK, Caffery B, DuaHS, JooCK, Liu Z, Nelson JD, Nichols JJ, TsubotaK, Stapleton F. TFOS DEWS II Definition and Classification Report. NOVARTIS STEPS UP DIGITAL STRATEGY FOR AMD TREATMENTS AND Novartis is doubling down on its mission to end preventable blindness, which has translated into a host of moves to strengthen its commitment to age-related macular degeneration (AMD) treatments and support. Its latest move is in the digital health space with the launch of a new feature on the MyTherapy app, a pill reminder and medication tracker shown to improve medication adherence.KFIR AZOULAY
Kfir Azoulay is Corporate Head of Strategy at Heidelberg Engineering, a technology leader in the field of ophthalmic diagnostic imaging systems and ophthalmic healthcare IT solutions (including PACS, EMR, and Data Analytics). In his current role, he oversees business development as well as the company’s other global strategicinitiatives.
HOW TO GET DEVICES APPROVED 510(k) Examples » “The SPECTRALIS is a non-contact ophthalmic diagnostic imaging device. It is intended for viewing the posterior segment of the eye, including two- and three-dimensional imaging, cross-sectional imaging (SPECTRALIS HRA+OCT and RISUTEGANIB (LUMINATE ): POTENTIAL PARADIGM SHIFT IN THE 2 Allegro is a late stage private biotech company focused on the treatment of retinal diseases Allegro’s lead investigational drug, Risuteganib(Luminate®), is a broad-spectrum anti-integrin peptide expected to begin phase 3 DME behance bloglovin dribbble email facebook flickr github gplus instagram linkedin medium periscope phone pinterest rss snapchat stumbleupon tumblr twitter vimeo xing youtube Call Us: 631-565-7203Subscribe
Subscribe Nominate
Skip to content
ALL MENU
__
__
Menu
* ABOUT US
* NEWS
* PODCASTS
* VIDEOS
* 2021 EVENTS
* Israel Innovation Showcase - June 10 * European Innovation Showcase - July 22 * Glaucoma Innovation Showcase - October 21 * Drug Delivery Innovation Showcase - November 11 * 2021 OIS Year in Review - December 2* - PAST EVENTS
* GET INVOLVED
* APPLY TO PRESENT
* BE OUR PODCAST GUEST * SPONSORSHIP OPPORTUNITIES* CONTACT US
CLOSE
ALL MENU
__
__
Menu
* ABOUT US
* NEWS
* PODCASTS
* VIDEOS
* 2021 EVENTS
* Israel Innovation Showcase - June 10 * European Innovation Showcase - July 22 * Glaucoma Innovation Showcase - October 21 * Drug Delivery Innovation Showcase - November 11 * 2021 OIS Year in Review - December 2* - PAST EVENTS
* GET INVOLVED
* APPLY TO PRESENT
* BE OUR PODCAST GUEST * SPONSORSHIP OPPORTUNITIES* CONTACT US
CLOSE
Play Video
OIS
------------------------- The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. The addition of experienced conference producer, Craig Simak brought the event to life in 2009.Learn More
EVENT UPDATES
------------------------- The Ophthalmology Innovation Source facilitates meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.LEARN MORE
__ VIEW FULL 2021 CALENDARTRENDING AT OIS
DISCOVER THE LATEST TRENDING NEWS, PODCASTS, VIDEOS FROM OIS COVERING CORPORATE LEADERS AND INNOVATORS. FUELED BY PASSION TO ADVANCE DEVELOPMENT – WITH STUART ABELSON OFORA
May 19, 2021
MICHAEL ONUSCHECK TAKES ALCON BACK TO THE BASICS TO MOVE FORWARDMay 11, 2021
EARNING THE RIGHT TO ASK FOR THE BUSINESS WITH NICK CURTIS OF LENSARMay 5, 2021
B+L’S CHUCK HESS IS LOOKING TO CHANGE THE GAME IN OPHTHALMOLOGYJune 2, 2021
FROM WORLD-CLASS ATHLETE TO PHARMA CEO WITH MICHELE GARUFI OF NICOXMay 25, 2021
FUELED BY PASSION TO ADVANCE DEVELOPMENT – WITH STUART ABELSON OFORA
May 19, 2021
MICHAEL ONUSCHECK TAKES ALCON BACK TO THE BASICS TO MOVE FORWARDMay 11, 2021
EARNING THE RIGHT TO ASK FOR THE BUSINESS WITH NICK CURTIS OF LENSARMay 5, 2021
B+L’S CHUCK HESS IS LOOKING TO CHANGE THE GAME IN OPHTHALMOLOGYJune 2, 2021
FROM WORLD-CLASS ATHLETE TO PHARMA CEO WITH MICHELE GARUFI OF NICOXMay 25, 2021
FUELED BY PASSION TO ADVANCE DEVELOPMENT – WITH STUART ABELSON OFORA
May 19, 2021
INNOVEGA IS MOVING QUICKLY IN AUGMENTED- AND VIRTUAL-REALITY SPACEMay 19, 2021
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASEMay 11, 2021
THE MYOPIA MANAGEMENT MARKET: ‘HOW BIG IS BIG?’May 4, 2021
OXURION NETS A FRESH $36 MILLION, NAMES NEW CEO AS CANDIDATES ADVANCEIN PIPELINE
June 2, 2021
THE FOUR TRENDS DRIVING THE DIGITAL SPACEMay 25, 2021
INNOVEGA IS MOVING QUICKLY IN AUGMENTED- AND VIRTUAL-REALITY SPACEMay 19, 2021
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASEMay 11, 2021
THE MYOPIA MANAGEMENT MARKET: ‘HOW BIG IS BIG?’May 4, 2021
OXURION NETS A FRESH $36 MILLION, NAMES NEW CEO AS CANDIDATES ADVANCEIN PIPELINE
June 2, 2021
THE FOUR TRENDS DRIVING THE DIGITAL SPACEMay 25, 2021
INNOVEGA IS MOVING QUICKLY IN AUGMENTED- AND VIRTUAL-REALITY SPACEMay 19, 2021
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASEMay 11, 2021
DESPITE INTERRUPTION, PIXIUM VISION AIMS TO KEEP MOVING TOWARD COMMERCIALIZING PRIMA SYSTEMApril 28, 2021
GYROSCOPE THERAPEUTICS COMPLETES FINANCING TO ADVANCE GENE THERAPYCANDIDATE FOR GA
April 20, 2021
THE FOUR TRENDS DRIVING THE DIGITAL SPACEMay 25, 2021
INNOVEGA IS MOVING QUICKLY IN AUGMENTED- AND VIRTUAL-REALITY SPACEMay 19, 2021
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASEMay 11, 2021
DESPITE INTERRUPTION, PIXIUM VISION AIMS TO KEEP MOVING TOWARD COMMERCIALIZING PRIMA SYSTEMApril 28, 2021
GYROSCOPE THERAPEUTICS COMPLETES FINANCING TO ADVANCE GENE THERAPYCANDIDATE FOR GA
April 20, 2021
THE FOUR TRENDS DRIVING THE DIGITAL SPACEMay 25, 2021
INNOVEGA IS MOVING QUICKLY IN AUGMENTED- AND VIRTUAL-REALITY SPACEMay 19, 2021
NOVARTIS-REGENERON DISPUTE ENTERS A NEW PHASEMay 11, 2021
OIS INDEX OUTPERFORMSDecember 4, 2019
OIS INDEX ON POSITIVE UPSWINGNovember 6, 2019
OIS INDEX DEEP IN BEAR TERRITORY IN Q3October 2, 2019
OIS INDEX RALLIES BACK FROM COVID-DRIVEN DECLINEJuly 9, 2020
OIS INDEX POSTS A STRONG FINISH TO 2019January 9, 2020
OIS INDEX OUTPERFORMSDecember 4, 2019
OIS INDEX ON POSITIVE UPSWINGNovember 6, 2019
OIS INDEX DEEP IN BEAR TERRITORY IN Q3October 2, 2019
OIS INDEX RALLIES BACK FROM COVID-DRIVEN DECLINEJuly 9, 2020
OIS INDEX POSTS A STRONG FINISH TO 2019January 9, 2020
OIS INDEX OUTPERFORMSDecember 4, 2019
DO YOU HAVE
A STORY TO TELL?
__
If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.Apply Today
TESTIMONIALS
WHY PEOPLE ATTEND OISTOM MITRO
PRESIDENT & COO
YARI MITCHELL
VP, GLOBAL MEDICAL AFFAIRSJAG DOSANJH
SENIOR VICE PRESIDENT SUBSCRIBE TO OUR NEWSLETTER Get the Latest News Ophthalmic Innovation To Your Inbox.Email Address *
First Name
Last Name
About OIS
Events List
News
Videos
OIS Podcast
OIS Index
Contact Us
Call Us: 1 (631) 565-7203GET INVOLVED
Apply To Present
Be Our Podcast Guest Sponsorship OpportunitiesMedia & Press
CONNECT WITH US
* YouTube
2020 · Ophthalmology Innovation Summit · Powered by Healthegy Terms & Conditions · Privacy Policy Scroll To Top__Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0